Neurol. praxi. 2019;20(1):17-20 | DOI: 10.36290/neu.2019.084

Indications of antithrombotic therapy for secondary stroke prevention

MUDr. Hana Magerová, Ph.D.
Neurologická klinika 2. LF UK a FN Motol, Praha

This article is related to previous articles in this issue discussing ischemic stroke. It provides an overview of antiplatelet and anticoagulation
therapy that is a crucial part of stroke secondary prevention. The article focuses on specifics and side-effects of each single medication,
on choosing appropriate therapy according to the stroke etiology and it also mentions some less common clinical situations.

Keywords: antiplatelet therapy, anticoagulation, ischemic stroke

Published: March 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Magerová H. Indications of antithrombotic therapy for secondary stroke prevention. Neurol. praxi. 2019;20(1):17-20. doi: 10.36290/neu.2019.084.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis SG, Kimura T, Nordaby M. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. New England Journal of Medicine 2017; 377(16): 1513-1524. Go to original source...
    2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996; 348(9038): 1329-1339. Go to original source... Go to PubMed...
    3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Wang S. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2009; 361(12): 1139-1151. Go to original source...
    4. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. The Lancet 2004; 364(9431): 331-337. Go to original source... Go to PubMed...
    5. Diener HC, Cunha L, Forbes CE, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the neurological sciences 1996; 143(1-2): 1-13. Go to original source... Go to PubMed...
    6. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The Lancet 2006; 367(9523): 1665-1673. Go to original source... Go to PubMed...
    7. European Stroke Organisation (ESO) Executive Committee, & ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular diseases 2008; 25(5): 457-507. Go to original source... Go to PubMed...
    8. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation, CIRCULATIONAHA-111.
    9. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Korjian S. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. New England Journal of Medicine 2016; 375(25): 2423-2434. Go to original source...
    10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Bahit MC. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2011; 365(11): 981-992. Go to original source...
    11. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B; Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine 1989; 321(8): 501-507. Go to original source...
    12. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Hoh BL. Stenting versus aggressive medical therapy for intracranial arterial stenosis. New England Journal of Medicine 2011; 365(11): 993-1003. Go to original source...
    13. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Wang Y. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. New England Journal of Medicine 2016; 375(1): 35-43. Go to original source...
    14. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Palesch YY. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine 2018. Go to original source... Go to PubMed...
    15. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Johnston SCC. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014, STR. 0000000000000024. Go to original source...
    16. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Hindricks G. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European heart journal 2016; 37(38): 2893-2962. Go to original source... Go to PubMed...
    17. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Archives of Internal Medicine 1999; 159(7): 677-685. Go to original source...
    18. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Horne BD. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Jama 2010; 304(16): 1821-1830. Go to original source... Go to PubMed...
    19. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43(12): 3298-3304. Go to original source... Go to PubMed...
    20. Sacco RL, Diener HC, Yusuf S, Cotton D, Ôunpuu S, Lawton WA, Bornstein N. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine 2008; 359(12): 1238-1251. Go to original source...
    21. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Jia J. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine 2013; 369(1): 11-19. Go to original source...
    22. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Riesmeyer J. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 2007; 357(20): 2001-2015. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.